| Year |
Citation |
Score |
| 2019 |
Raj N, Bam R. Reciprocal Crosstalk Between YAP1/Hippo Pathway and the p53 Family Proteins: Mechanisms and Outcomes in Cancer. Frontiers in Cell and Developmental Biology. 7: 159. PMID 31448276 DOI: 10.3389/Fcell.2019.00159 |
0.333 |
|
| 2018 |
Boyko TV, Bam R, Jiang D, Wang Z, Bhatia N, Tran MC, Longaker MT, Koong AC, Yang GP. Inhibition of IRE1 Results in Decreased Scar Formation. Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society. PMID 29316036 DOI: 10.1111/Wrr.12603 |
0.302 |
|
| 2016 |
Jiang D, Lynch C, Medeiros BC, Liedtke M, Bam R, Tam AB, Yang Z, Alagappan M, Abidi P, Le QT, Giaccia AJ, Denko NC, Niwa M, Koong AC. Identification of Doxorubicin as an Inhibitor of the IRE1α-XBP1 Axis of the Unfolded Protein Response. Scientific Reports. 6: 33353. PMID 27634301 DOI: 10.1038/Srep33353 |
0.411 |
|
| 2015 |
Bam R, Khan S, Ling W, Randal SS, Li X, Barlogie B, Edmondson R, Yaccoby S. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. Bmc Cancer. 15: 864. PMID 26545722 DOI: 10.1186/S12885-015-1892-7 |
0.72 |
|
| 2014 |
Bam R, Venkateshaiah SU, Khan S, Ling W, Randal SS, Li X, Zhang Q, van Rhee F, Barlogie B, Epstein J, Yaccoby S. Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells. Blood Cancer Journal. 4: e234. PMID 25083818 DOI: 10.1038/Bcj.2014.54 |
0.753 |
|
| 2014 |
Johnson SK, Stewart JP, Bam R, Qu P, Barlogie B, van Rhee F, Shaughnessy JD, Epstein J, Yaccoby S. CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease. Blood. 124: 2051-60. PMID 25061178 DOI: 10.1182/Blood-2014-02-555813 |
0.711 |
|
| 2014 |
Bam R, Edmondson RD, Stein CK, Li X, Ling W, Khan S, Shelton RS, Barlogie B, Yaccoby S. Sustained Growth of Primary Myeloma Cells in Coculture with Whole Donor Bone Marrow Is Associated with Induced Secretion of the Microenvironmental Mediator of Cytokinesis, Hemicentin-1 Blood. 124: 3403-3403. DOI: 10.1182/Blood.V124.21.3403.3403 |
0.755 |
|
| 2013 |
Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, van Rhee F, Usmani S, Barlogie B, Shaughnessy J, Epstein J, Yaccoby S. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. American Journal of Hematology. 88: 463-71. PMID 23456977 DOI: 10.1002/Ajh.23433 |
0.752 |
|
| 2013 |
Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Experimental Hematology. 41: 547-557.e2. PMID 23435312 DOI: 10.1016/j.exphem.2013.02.008 |
0.746 |
|
| 2013 |
Bam R, Venkateshaiah SU, Li X, Khan S, Ling W, Shelton RS, Zhang Q, Barlogie B, Epstein J, Yaccoby S. Inhibition Of BTK Activity In Myeloma Cells Within a Supportive Microenvironment Promotes Their Growth But Suppresses Metastasis Blood. 122: 4432-4432. DOI: 10.1182/Blood.V122.21.4432.4432 |
0.773 |
|
| 2013 |
venkateshaiah SU, Bam R, Li X, Khan S, Ling W, Randal S S, Yaccoby S. GPRC5D Is a Cell Surface Plasma Cell Marker Whose Expression Is High In Myeloma Cells and Reduced Following Coculture With Osteoclasts Blood. 122: 3099-3099. DOI: 10.1182/Blood.V122.21.3099.3099 |
0.72 |
|
| 2013 |
Venkateshaiah SU, Bam R, Li X, Sharmin K, Wen L, Shelton RS, Teige I, Frendéus B, Barlogie B, Yaccoby S. Macrophages Activation By ICAM1 Antibody Combined With Lenalidomide Has Enhanced Anti-Myeloma Activity In a Supportive Microenvironment In Vivo and In Vitro Blood. 122: 1926-1926. DOI: 10.1182/Blood.V122.21.1926.1926 |
0.741 |
|
| 2013 |
Bam R, Venkateshaiah SU, Li X, Khan S, Ling W, Barlogie B, Epstein J, Yaccoby S. Abstract 1648: Primary myeloma plasma cells are capable of growth in adult, normal whole human bone marrow environment . Cancer Research. 73: 1648-1648. DOI: 10.1158/1538-7445.Am2013-1648 |
0.731 |
|
| 2012 |
Upparahallivenkateshaiah S, Sharmin K, Wen L, Bam R, Li X, Yaccoby S. Upregulation of Lipid Metabolism Modulators in Myeloma Cells Underlines Their Progression in a Supportive Microenvironment and Linking Metabolic Pathways with Growth Signaling Blood. 120: 329-329. DOI: 10.1182/Blood.V120.21.329.329 |
0.698 |
|
| 2012 |
Li X, Ling W, Khan S, Venkateshaiah SU, Bam R, Barlogie B, Epstein J, Yaccoby S. HMOX1 Is a Targeted Therapy for Myeloma-Induced Bone Disease. Blood. 120: 2944-2944. DOI: 10.1182/Blood.V120.21.2944.2944 |
0.707 |
|
| 2011 |
Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, Williams R, van Rhee F, Nair B, Usmani S, Barlogie B, Shaughnessy JD, Epstein J, Yaccoby S. Cell Surface CXCR4 and BTK Expression Are Associated in Myeloma Cells and Osteoclast Precursors and Mediate Myeloma Cell Homing and Clonogenicity, and Osteoclastogenesis Blood. 118: 884-884. DOI: 10.1182/Blood.V118.21.884.884 |
0.754 |
|
| 2011 |
Venkateshaiah SU, Khan S, Ling W, John LS, Bam R, Li X, Yaccoby S. Stearoyl CoA Desaturase 1 (SCD1) Is Upregulated in Rapidly Growing Myeloma Cells and Is Required for Cell Proliferation Blood. 118: 3943-3943. DOI: 10.1182/Blood.V118.21.3943.3943 |
0.744 |
|
| 2011 |
Bam R, Ling W, Khan S, Venkateshaiah SU, Li X, van Rhee F, Nair B, Usmani S, Barlogie B, Shaughnessy JD, Epstein J, Anaissie EJ, Yaccoby S. Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and Osteoclasts, and Promote Myeloma Growth and Bone Disease, Blood. 118: 3941-3941. DOI: 10.1182/Blood.V118.21.3941.3941 |
0.735 |
|
| 2010 |
Bam R, Pennisi A, Li X, Khan S, Wang Y, Ling W, Barlogie B, Shaughnessy J, Yaccoby S. Bruton's Tyrosine Kinase (BTK) Is Indispensable for Myeloma Cell Migration towards SDF-1 and Induction of Osteoclastogenesis and Osteolytic Bone Disease Blood. 116: 447-447. DOI: 10.1182/Blood.V116.21.447.447 |
0.736 |
|
| Show low-probability matches. |